【OBHB 0327 交流专区】

icy97

IPO Prospectus

OB HOLDINGS BERHAD

Subject

INITIAL PUBLIC OFFERING ("IPO") IN CONJUNCTION WITH THE LISTING OF OB HOLDINGS BERHAD ("OB HOLDINGS" OR "COMPANY") ON THE ACE MARKET OF BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") COMPRISING PUBLIC ISSUE OF 120,000,000 NEW ORDINARY SHARES IN OB HOLDINGS ("SHARES") IN THE FOLLOWING MANNER: (I) 19,582,000 NEW SHARES MADE AVAILABLE FOR APPLICATION BY THE MALAYSIAN PUBLIC; (II) 7,833,000 NEW SHARES MADE AVAILABLE FOR APPLICATION BY OUR ELIGIBLE DIRECTORS, EMPLOYEES AND PERSONS WHO HAVE CONTRIBUTED TO THE SUCCESS OF OUR GROUP; (III) 43,632,000 NEW SHARES MADE AVAILABLE BY WAY OF PRIVATE PLACEMENT TO SELECTED INVESTORS; AND (IV) 48,953,000 NEW SHARES MADE AVAILABLE BY WAY OF PRIVATE PLACEMENT TO SELECTED BUMIPUTERA INVESTORS APPROVED BY THE MINISTRY OF INVESTMENT, TRADE AND INDUSTRY OF MALAYSIA; AT AN IPO PRICE OF RM0.24 PER SHARE, PAYABLE IN FULL UPON APPLICATION.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3486821

Attachments OBH - English IPO (Bursa) Part 1.pdf OBH - English IPO (Bursa) Part 2.pdf OBH - Detailed Procedures.pdf

Opening of application	27 Sep 2024
Closing of application	15 Oct 2024
Balloting of application	18 Oct 2024
Allotment of IPO shares to successful applicants	25 Oct 2024
Tentative listing date	29 Oct 2024

icy97

Type	Announcement
Subject	OTHERS
Description	OB HOLDINGS BERHAD ("OB HOLDINGS" OR "COMPANY")INITIAL PUBLIC OFFERING IN CONJUNCTION WITH THE LISTING OF OB HOLDINGS ON THE ACE MARKET OF BURSA MALAYSIA SECURITIES BERHAD ("IPO")
On behalf of the Board of Directors of OB Holdings, Alliance Islamic Bank Berhad is pleased to announce the following in relation to the IPO: (i)       level of subscription of public balloting and placement; (ii)      basis of allotment/allocation; (iii)     distribution for the placement tranche; and (iv)     disclosure of placees who become substantial shareholder of OB Holdings arising from the IPO, if any. Further details of the above are set out in the attachment. This announcement is dated 18 October 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3492692

Attachments 1.OB - IPO Subscription.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Aug 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Aug 2024	31 Aug 2023	31 Aug 2024	31 Aug 2023
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	12,022	0	12,022	0
2	Profit/(loss) before tax	2,005	0	2,005	0
3	Profit/(loss) for the period	1,442	0	1,442	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,442	0	1,442	0
5	Basic earnings/(loss) per share (Subunit)	2.69	0.00	2.69	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.1200		0.1200

icy97

Type	Announcement
Subject	OTHERS
Description	OB HOLDINGS BERHAD ("OB HOLDINGS" OR "COMPANY")DISPUTE ON ALLEGED BREACH OF CONTRACT AND INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS WITH NATURE ONE DAIRY (HONG KONG) LIMITED ("DISPUTE")
On behalf of the Board of Directors of the Company (“Board”), Alliance Islamic Bank Berhad wishes to announce that Orient Biotech Sdn Bhd (“Orient Biotech”), a wholly-owned subsidiary of the Company, has on 22 October 2024, received a letter from a law firm acting for Nature One Dairy (Hong Kong) Limited (“NOD”), a customer of OB Holdings and its subsidiaries (“OB Holdings Group” or “Group”) alleging that Orient Biotech is in breach of the purchase & supply agreement dated 28 September 2022 entered into between Orient Biotech and NOD (“NOD Agreement”) and has infringed intellectual property rights of NOD (“Dispute Notice”). NOD has invoked a Dispute Notice as stipulated in Clause 15.1 of the NOD Agreement, which states if any dispute or difference arises between the parties in respect of any matter relating to the NOD Agreement or a breach thereof, the party claiming that a Dispute has arisen must notify the other party in writing giving details of the Dispute. Pursuant to the Dispute Notice, Orient Biotech has been requested by NOD to provide a written confirmation that it will cease and desist from any dealings in respect of manufacture of a certain milk powder product (“Relevant Product”) for a particular new customer of the Group in which the relationship was established in August 2024 (“Relevant Customer”), and provide full discovery of all dealings related to the Relevant Product and offer all necessary assistance to NOD in taking legal action against parties or person who engaged Orient Biotech in respect of the Relevant Product within 14 days from the date of the Dispute Notice. Based on the Dispute Notice, NOD is alleging that Orient Biotech is in breach of Clause 13.5 of the NOD Agreement for infringement of NOD’s intellectual property rights for manufacturing the Relevant Product for the Relevant Customer using formulations, recipes and ingredients which are identical or very similar to NOD’s formulations, recipes and ingredients for NOD’s milk powder products manufactured by Orient Biotech for NOD. Orient Biotech has engaged solicitors (“Solicitors”) to advise on the Dispute and has via a letter dated 24 October 2024 issued by its Solicitors denied the allegations made by NOD in the Dispute Notice, in particular that NOD does not hold any distinctive and classifiable intellectual property rights in respect of the formulation, recipe or ingredients of the Relevant Product as they contain generic ingredients used in similar products which are commonly available in the market. Orient Biotech has requested that NOD to provide the basis or particulars of its claims pursuant to Clause 15.1 of the NOD Agreement, given that the contents of the Dispute Notice are inadequate to sufficiently determine the basis or merits of its claim. Further to the demand from NOD in the Dispute Notice, Orient Biotech has agreed on a without prejudice and without admission of liability basis to cease manufacturing of the Relevant Product to the Relevant Customer provided that NOD’s claims are established by evidence. However, Orient Biotech has put NOD on notice that it will hold NOD liable and seek full indemnification from NOD from and against all losses, damages, claims, expenses, proceedings, suits, legal costs (on a solicitor and client basis) that Orient Biotech may suffer as a consequence of the Dispute Notice, including but not limited to arising from compliance with NOD’s cease and desist demand, if NOD’s claims are found to be unsubstantiated or without merit. Orient Biotech is in the midst of pursuing the dispute resolution mechanism as stipulated in the NOD Agreement to use its best efforts to resolve the Dispute amicably by discussions and negotiation with NOD within 30 days from the date of the Dispute Notice, failing which the Dispute shall be referred to mediation in accordance with the terms of the NOD Agreement. Based on the opinion provided by the Solicitors, Orient Biotech has received advice that: Based on the presented facts, there are differences between formulations and ingredients of the Relevant Product and NOD’s milk powder products. The common ingredients are generic and found in other products with similar purposes and benefits. There is sufficient basis to argue that Orient Biotech did not breach the NOD Agreement, and there was no unauthorised use of the product formulations. In addition, NOD’s claim lacks substantive support, as the Dispute Notice only asserts similarities without specific details to substantiate the allegations. The Board is of the opinion that the Dispute is not expected to impact the Group’s financial and operational positions materially based on the following: The amount of purchase orders to-date from the Relevant Customer only amounted to about RM0.57 million and have been fully delivered. The potential loss of sale from the Relevant Customer arising from the temporary cessation of sale is not expected to have material impact to the Group; and The Group has recorded a decrease in revenue from NOD, from RM3.73 million (8.02% of revenue), RM1.38 million (2.71% of revenue), and Nil for FYE 2023, FYE 2024 and unaudited financial period ended 31 August 2024, respectively. In addition, there is currently no outstanding purchase orders from NOD. The sale to NOD was after the acquisition of the milk powder business and brand of Fei Fah Medical Sdn Bhd by Nature One Dairy Pty Ltd on 16 May 2022.  As a result, the Group’s manufacturing services of milk powder was redirected to Nature One Dairy Pty Ltd’s milk powder facility in Hong Kong which is held by NOD. The Group does not anticipate significant sales from NOD in future. The Group would focus on procuring sales from new and existing customers moving forward. This announcement is dated 25 October 2024.

icy97

Initial Public Offering

OB HOLDINGS BERHAD

Date of Listing	29 Oct 2024
Enlarged Issued Share Capital in the following
Units	391,627,000
Currency	Malaysian Ringgit (MYR)
Par Value (if applicable)
Enlarged Issued Share Capital	55,963,600.000
Stock Code	0327
Stock Name	OBHB
ISIN code	MYQ0327OO005
Board	ACE Market
Bursa Sector	CONSUMER PRODUCTS & SERVICES
Bursa Sub Sector	FOOD& BEVERAGES
Do you wish to list any child stock / new type of securities in conjunction with the IPO/Admission to LEAP Market?	No

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Nov 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Nov 2024	30 Nov 2023	30 Nov 2024	30 Nov 2023
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	12,683	0	24,705	0
2	Profit/(loss) before tax	851	0	2,856	0
3	Profit/(loss) for the period	257	0	1,699	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	257	0	1,699	0
5	Basic earnings/(loss) per share (Subunit)	0.19	0.00	1.29	0.00
6	Proposed/Declared dividend per share (Subunit)	0.12	0.00	0.12	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.1600		0.1200

icy97

OB HOLDINGS BERHAD

Entitlement subject	Interim Dividend
Entitlement description	Interim Dividend of 0.12 sen per ordinary share
Ex-Date	03 Mar 2025
Entitlement date	04 Mar 2025
Entitlement time	5:00 PM
Financial Year End	31 May 2025
Period
Share transfer book & register of members will be	to  closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	14 Mar 2025
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	04 Mar 2025
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0012

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 28 Feb 2025

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		28 Feb 2025	28 Feb 2024	28 Feb 2025	28 Feb 2024
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	13,895	0	38,600	0
2	Profit/(loss) before tax	1,828	0	4,684	0
3	Profit/(loss) for the period	1,152	0	2,850	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,152	0	2,850	0
5	Basic earnings/(loss) per share (Subunit)	0.50	0.00	1.25	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.12	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.1600		0.1200

icy97

Type	Announcement
Subject	OTHERS
Description	OB HOLDINGS BERHAD ("OB HOLDINGS" OR "THE COMPANY")- LETTERS OF INTENT ENTERED INTO BY ORIENT BIOTECH SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY, WITH CSPC INNOVATION PHARMACEUTICAL CO., LTD. AND CSPC WEISHENG PHARMACEUTICAL (SHIJIAZHUANG) CO., LTD., BOTH SUBSIDIARIES OF CSPC PHARMACEUTICAL GROUP LIMITED
The Board of Directors of OB Holdings wishes to announce that, Orient Biotech Sdn. Bhd., a wholly-owned subsidiary of the Company had on 2 May 2025 entered into two (2) separate Letters of Intent, with CSPC Innovation Pharmaceutical Co., Ltd. and CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., both subsidiaries of CSPC Pharmaceutical Group Limited. Please refer to the attachment for the details of this announcement. This announcement is dated 2 May 2025.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3550862

Attachments OB Holdings - Annc.pdf OB Holdings - Press Release.pdf